TSLA
Tesla
-- 424.770 NVDA
NVIDIA
-- 139.310 PLTR
Palantir
-- 72.510 RGTI
Rigetti Computing
-- 7.3800 SMCI
Super Micro Computer
-- 38.290 
NEWS
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
Tuesday, 10th December at 8:00 am
~ Supply Chain Now Fully Secure for PF614-MPAR ~
SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the receipt of commitment of future supply of GMP nafamostat, a critical component of PF614-MPAR. This agreement fully secures the supply chain and allows Ensysce to reference the nafamostat Drug Master File of Aurore Life Sciences, a renowned specialty drug manufacturer.
Dr. Lynn Kirkpatrick commented, "We are pleased to have received this early interest and commitment from Aurore as nafamostat is a vital component of our overdose protection program PF614-MPAR. Having a secure supply of this drug substance will accelerate our finalizing the drug product for PF614-MPAR, which is rapidly moving through clinical development. Ensysce has initiated additional programs with nafamostat as a single agent for other indications which will also benefit from this commitment, so we welcome Aurore as a critical partner in our pipeline development."
Tuesday, 10th December at 8:00 am
~ Supply Chain Now Fully Secure for PF614-MPAR ~
SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the receipt of commitment of future supply of GMP nafamostat, a critical component of PF614-MPAR. This agreement fully secures the supply chain and allows Ensysce to reference the nafamostat Drug Master File of Aurore Life Sciences, a renowned specialty drug manufacturer.
Dr. Lynn Kirkpatrick commented, "We are pleased to have received this early interest and commitment from Aurore as nafamostat is a vital component of our overdose protection program PF614-MPAR. Having a secure supply of this drug substance will accelerate our finalizing the drug product for PF614-MPAR, which is rapidly moving through clinical development. Ensysce has initiated additional programs with nafamostat as a single agent for other indications which will also benefit from this commitment, so we welcome Aurore as a critical partner in our pipeline development."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment